A drug used to reduce cholesterol and protect against cardiovascular disease may improve bone repair in patients with neurofibromatosis type 1 (NF1), results of an animal study suggest.

Lab research conducted at the Max Planck Institute for Molecular Genetics, Berlin, found that the drug Lovastatin aids bone healing in a mouse model of human NF1 disease.

The study examined the process of bone repair seven days, 14 days and 28 days after the researchers drilled a 0.5mm hole in the tibia of anaesthetised mice.

According to the results, mice given the statin treatment showed notable improvements in bone repair compared to the control models.

Commenting on the findings, lead researcher Mateusz Kolanczyk said: "Our results suggest the usefulness of lovastatin, a drug approved in 1987 for the treatment of high cholesterol, in the treatment of neurofibromatosis-related fracture healing abnormalities."

Common symptoms of NF1 include bowing, spontaneous fractures and pseudarthrosis (incomplete healing) of the tibia.

At present, therapies used to treat pseudarthrosis of the tibia are mostly ineffective and often result in the need for amputation.

Login and visit the Cholesterol Knowledge CentreRegister now to access our FREE educational library

• Cholesterol treatment receives US approval 16/12/08
• Study confirms no interference between cholesterol and lymphoma treatments 09/12/08
• New game could help tackle obesity and diabetes in kids, expert claims 04/12/08
• Some "good cholesterol" not good enough, study suggests 02/12/08
• Study links grapes with reduced cardio risk 29/10/08

• ZOCOR (statin) - 51.11%
  ... cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate. To lower LDL:HDL ratio and total cholesterol ...
  
  
• LIPITOR (statin) - 50.64%
  Adjunct to diet for reduction of elevated total cholesterol, LDL- cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia, heterozygous and homozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non ...
  
  
• Simvastatin (statin) - 50.64%
  As an adjunct to diet for reduction of total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate ...
  
  
• LESCOL XL (statin) - 49.42%
  As an adjunct to diet for the reduction of elevated total cholesterol (total-C), low- density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B) and triglycerides (TG) levels and for the increase of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolaemia ...
  
  
• LIPOSTAT (statin) - 48.68%
  ... procedure in patients with a history of either a myocardial infarction or unstable angina pectoris and a total serum cholesterol level in excess of 4.8mmol/L or a LDL- cholesterol in excess of 3.2mmol/ L. Coronary atherosclerotic disease: adjunct to diet to slow progressve course of coronary ...
  
  
• CHOLESTAGEL Film-Coated Tablets - 47.95%
  ... reduction in LDL-cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total and LDL-cholesterol in patients with isolated ...